Shots:

• MD Anderson will sponsor and lead P-I/II study to assess DS-1594 as monothx. and in combination regimens for patients with r/r AML and ALL
• The 1EPs of the P-I part of the study is to determine the maximum tolerated dose and RP2D of DS-1594 in ~54 patients with AML or ALL regardless of mutation status. The 2EPs include CR and CR with CRh
• The P-II part of the study will evaluate DS-1594 at the established dose in four expansion cohorts of patients with specific genetic markers. The study enrolled ~170 patients which will initially be conducted only at MD Anderson with global expansion planned for P-II

  Ref: BusinessWire | Image: The Japan Times